Monopar Starts Rolling NDA for ALXN1840 Wilson
Monopar ALXN1840 rolling NDA for Wilson disease is underway at FDA. The company said on July 24, 2026 that it started submitting modules for tiomolybdate choline after receiving Fast Track designation for the rare copper-metabolism disorder.
Contents9 sections
Key Takeaways
- Monopar initiated a rolling NDA for ALXN1840 (tiomolybdate choline) in Wilson disease.
- FDA Fast Track designation supports more frequent agency interactions and rolling review eligibility.
- Wilson disease is a rare genetic copper-overload disorder with hepatic and neurologic sequelae.
- Final NDA completeness, review classification, and PDUFA timing were not disclosed in the start notice.
ALXN1840 rolling NDA at a glance
| Field | Detail |
|---|---|
| Candidate | ALXN1840 (tiomolybdate choline) |
| Company | Monopar Therapeutics Inc. |
| Indication | Wilson disease |
| FDA action | Rolling NDA initiation announced July 24, 2026 |
| Designation | Fast Track (company) |
| Modality | Oral copper-binding agent |
| Next milestone | Complete NDA module submissions; FDA filing acceptance |
What did Monopar announce?
Monopar said it began a rolling NDA for ALXN1840, allowing completed sections of the application to be filed as they are ready rather than waiting for a single simultaneous package. The company positioned the program as a potential new option for people with Wilson disease who still face adherence, tolerability, or efficacy gaps on existing therapies.
Source: Monopar's July 24 PR Newswire rolling-NDA release.
What is Wilson disease?
Wilson disease is an autosomal recessive disorder of copper transport that can present with hepatitis, cirrhosis, psychiatric symptoms, or movement disorders. Without treatment, progressive copper accumulation can be life-threatening. U.S. care pathways commonly use copper chelators and zinc salts; transplant remains an option for fulminant hepatic failure.
Clinical-trial context for Wilson disease interventions can be browsed on ClinicalTrials.gov.
What does Fast Track change for the NDA?
- More frequent FDA meetings and written advice
- Eligibility for rolling review when criteria are met
- Potential for Priority Review if a subsequent request is granted
FDA's Fast Track and rolling-review framework is described on FDA's Fast Track page. For a rare-disease filing, those interactions matter because CMC scale-up, long-term safety follow-up, and neurologic endpoint interpretation often drive review questions as much as the primary efficacy table.
Wilson disease clinicians will still need labeled dosing, monitoring of copper parameters, and guidance on transitions from existing chelators before any commercial use is possible. Until FDA accepts and reviews a complete application, ALXN1840 remains investigational, and patients should continue established disease management under specialist care.
What remains uncertain?
Initiating a rolling NDA is not the same as filing acceptance or approval. Monopar did not publish a complete-module target date, review designation request, or pivotal-trial data summary in the start wire. Benefit-risk will rest on the full clinical and CMC package once FDA dockets the application.
Related NovaPharma coverage
- FDA Activity Round Up July 2026
- Revolution Medicines submits NDA for daraxonrasib
- Dyne submits BLA for z-rostudirsen in DMD
Frequently Asked Questions
What did Monopar start with FDA for ALXN1840?
On July 24, 2026, Monopar Therapeutics said it initiated a rolling New Drug Application to the FDA for ALXN1840 (tiomolybdate choline) for the treatment of Wilson disease. Rolling review lets the company submit completed NDA modules as they are finished.
Does ALXN1840 have Fast Track status?
Yes. Monopar said the FDA previously granted Fast Track designation for ALXN1840 in Wilson disease, which can support more frequent FDA interactions and potential eligibility for rolling review.
What is Wilson disease and why does copper chelation matter?
Wilson disease is a rare genetic disorder of copper metabolism that can cause hepatic and neurologic injury if untreated. Current U.S. options include chelators and zinc; Monopar is developing ALXN1840 as an oral copper-binding agent intended to address remaining unmet need.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for ALXN1840.
Unlock full calendar →Monopar Therapeutics pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives — Patient and care partner perspectives inform FDA’s thinking on approved gene therapy safety and long…